OPL-0401 for Diabetic Retinopathy
(Spectra Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called OPL-0401 to help people with diabetes who have eye problems. It focuses on patients with diabetic retinopathy, aiming to see if the treatment can reduce eye damage and improve or preserve their vision.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that your diabetes and blood pressure should be controlled, which might require continuing your current treatments.
Who Is on the Research Team?
Victor Shi, M.D.
Principal Investigator
Valo Health, Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 18 with diabetic retinopathy, a condition affecting the retina due to diabetes. Participants can have mild vision impairment but must not be extremely overweight or have uncontrolled diabetes or blood pressure. They shouldn't need other eye treatments for 6 months and haven't had recent eye surgery or certain past treatments like laser photocoagulation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive OPL-0401 or placebo twice daily for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- OPL-0401
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Valo Health, Inc.
Lead Sponsor